Диссертация (1140142), страница 17
Текст из файла (страница 17)
‒ Vol. 16, № 3. ‒ P. 208-214.76. Anbar T.S., El-Ammawi T.S., Abdel-Rahman A.T., Hanna M.R. Theeffect of latanoprost on vitiligo: a preliminary comparative study // Int J Dermatol.‒ 2015. ‒ Vol. 54, № 5. ‒ P. 587-9377. Anbar T.S., Westerhof W., Abdel-Rahman A.T., El-Khayyat M.A.Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligoaffecting different body sites // Photodermatol. Photoimmunol. Photomed. ‒ 2006.‒ Vol. 22, № 3. ‒ P. 157-16378. Anitua E., Orive G., Pla R.
et al. The effects of PRGF on boneregeneration and on titanium implant osseointegration in goats: a histologic andhistomorphometric study // J. Biomed Mater Res A. - 2009. - Vol. 91. - P. 158–165.79. Ardigo M., Malizewsky I., Dell'anna M.L. et al. Preliminaryevaluation of vitiligo using in vivo reflectance confocal microscopy // J. Eur. Acad.Dermatol. Venereol. ‒ 2007. ‒ Vol. 21, № 10. ‒ P. 1344-1350.80.
Ashique K.T., Kaliyadan F. Long-Term Follow-up and Donor SiteChanges Evaluation in Suction Blister Epidermal Grafting Done for StableVitiligo: A Retrospective Study // Indian. J. Dermatol. ‒ 2015. ‒ Vol. 60, № 4. ‒ P.108369-372.81. Averbeck D. Recent advances in psoralen phototoxicity mechanism //Photochem. Photobiol. ‒ 1989. ‒ Vol. 50, № 6. ‒ P. 859-882.82.
Babiarz-Magee L., Chen N., Seiberg M. et al. The expression andactivation of protease-activated receptor-2 correlate with skin color // Pigment CellRes. - 2004.- Vol.17 (3). - P.241-251.83. Bae J.M., Jung H.M., Hong B.Y. et al. Phototherapy for Vitiligo: ASystematic Review and Meta-analysis // JAMA Dermatol. ‒ 2017. ‒ Vol.
153, №7. ‒ P. 666-674.84. Barygina V., Becatti M., Lotti T. et al. Treatment with low-dosecytokines reduces oxidative-mediated injury in perilesional keratinocytes fromvitiligo skin // J. Dermatol. Sci. - 2015. - Vol.79 (2). - P.163-170.85. Beebe A.M., Cua D.J., de Waal Malefyt R. The role of interleukin-10in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis(MS) // Cytokine Growth Factor Rev. - 2002. - Vol.13.
- P.403-412.86. Behm B., Babilas P., Landthaler M., Schreml S. Cytokines,chemokines and growth factors in wound healing // J. Eur. Acad. Dermatol.Venereol. ‒ 2012. ‒ Vol. 26, № 7. ‒ P. 812-820.87. Bellet J.S., Prose N.S. Vitiligo in children: a review of classification,hypotheses of pathogenesis and treatment // An. Bras.
Dermatol. - 2005. - Vol. 80(6). - P.633-637.88. Bendinelli P., Matteucci E., Dogliotti G. et al. Molecular basis of antiinflammatory action of platelet-rich plasma on human chondrocytes: mechanismsof NF-kappaB inhibition via HGF // J. Cell. Physiol. ‒ 2010. ‒ Vol. 225, № 3. ‒ P.757-766.89. Berlanga-Acosta J., Gavilondo-Cowley J., Lopez-Saura P. et al.Epidermal growth factor in clinical practice - a review of its biological actions,clinical indications and safety implications // Int. Wound. J. ‒ 2009. ‒ Vol. 6, № 5.‒ P. 331-34690. Bernuzzi G., Tardito S., Bussolati O.
et al. Platelet gel in the treatment109of cutaneous ulcers: the experience of the immunohaematology and transfusioncentre of parma // Blood Transfus. - 2010. - Vol. 8. - P. 237–247.91. Bertolotti A., Boniface K., Vergier B. et al.
Type I interferon signaturein the initiation of the immune response in vitiligo // Pigment Cell Melanoma Res.‒ 2014. ‒ Vol. 27, № 3. ‒ P. 398-407.92. Boniface K., Seneschal J., Picardo M., Taieb A. Vitiligo: Focus onClinical Aspects, Immunopathogenesis, and Therapy // Clin. Rev. Allergy.Immunol. ‒ Epub 2017 July 6.93. Boswell S.G., Cole B.J., Sundman E.A.
et al. Platelet-rich plasma: amilieu of bioactive factors // Arthroscopy. ‒ 2012. ‒ Vol. 28, № 3. ‒ P. 429-439.94. Campbell K.A., Saltzman B.M., Mascarenhas R. et al. Does Intraarticular Platelet-Rich Plasma Injection Provide Clinically Superior OutcomesCompared With Other Therapies in the Treatment of Knee Osteoarthritis? ASystematic Review of Overlapping Meta-analyses // Arthroscopy. ‒ 2015.
‒ Vol.31, № 11. ‒ P. 2213-2221.95. Casacci M., Thomas P., Pacifico A. et al. Comparison between 308nm monochromatic excimer light and narrowband UVB phototherapy (311-313nm) in the treatment of vitiligo ‒ a multicentre controlled study // J. Eur. Acad.Dermatol. Venereol. ‒ 2007. ‒ Vol. 21, № 7. ‒ P. 956-963.96. Cavalie M., Ezzedine K., Fontas E. et al.
Maintenance therapy of adultvitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebocontrolled study // J. Invest. Dermatol. ‒ 2015. ‒ Vol. 135, № 4. ‒ P. 970-974.97. Cesar Silva de Castro C., Miot H.A. Prevalence of vitiligo in Brazil-Apopulation survey // Pigment Cell Melanoma Res. - 2018. - Vol.31(3). - P.448-450.98. Chan M.F., Thng T.G., Aw C.W. et al. Investigating factors associatedwith quality of life of vitiligo patients in Singapore // Int J Nurs Pract. - 2013. Vol.19. - P.3-10.99.
Cheong K.A., Noh M., Kim C.H. et al. S100B as a potentialbiomarker for the detection of cytotoxicity of melanocytes // Exp. Dermatol. 2014. - Vol.23 (3). - P.165-171.110100. Cho J.W., Kim S.A., Lee K.S. Platelet-rich plasma induces increasedexpression of G1 cell cycle regulators, type I collagen, and matrixmetalloproteinase-1 in human skin fibroblasts // Int. J.
Mol. Med. - 2012. - Vol.29.- P.32 –36.101. Choi C.P., Kim Y.I., Lee J.W., Lee M.H. The effect of narrowbandultraviolet B on the expression of matrix metalloproteinase-1, transforming growthfactor-beta1 and type I collagen in human skin fibroblasts // Clin Exp Dermatol.
2007. - Vol.32. - P.180-185.102. Choi H.R., Shin J.W., Lee H.K. et al. Potential redox-sensitive Aktactivation by dopamine activates Bad and promotes cell death in melanocytes //Oxid Med Cell Longev. - 2010.- Vol.3(3). - P.219-224.103. Chu T.W., AlJasser M., Alharbi A., Abahussein O., McElwee K.,Shapiro J. Benefit of different concentrations of intralesional triamcinoloneacetonide in alopecia areata: An intrasubject pilot study // J. Am Acad. Dermatol.
‒2015. ‒ Vol.73, №2. ‒ P. 338-340.104. Cichorek M., Wachulska M., Stasiewicz A. et al. Skin melanocytes:biology and development // Postepy Dermatol Alergol. - 2013. - Vol.30(1). - P.3041.105. Coppinger J.A., Cagney G., Toomey S. et al. Characterization of theproteins released from activated platelets leads to localization of novel plateletproteins in human atherosclerotic lesions // Blood. ‒ 2004. ‒ Vol. 103, № 6. ‒ P.2096-2104.106.
Coskun B., Saral Y., Turgut D. Topical 0.05% clobetasol propionateversus 1% pimecrolimus ointment in vitiligo // Eur. J. Dermatol. ‒ 2005. ‒ Vol. 15,№ 2. ‒ P. 88-91.107. Das S.K., Majumder P.P., Chakraborty R. et al. Studies on vitiligo. I.Epidemiological profile in Calcutta, India // Genet. Epidemiol. ‒ 1985. ‒ Vol. 2, №1. ‒ P. 71-78.108. Davis V.L., Abukabda A.B., Radio N.M. et al.
Platelet-richpreparations to improve healing. Part I: workable options for every size practice //111J. Oral. Implantol. ‒ 2014. ‒ Vol. 40, № 4. ‒ P. 500-510.109. Dell'anna M.L., Picardo M. A review and a new hypothesis for nonimmunological pathogenetic mechanisms in vitiligo // Pigment Cell Res. ‒ 2006. ‒Vol. 19, № 5. ‒ P.
406-411.110. Denapoli P.M., Stilhano R.S., Ingham S.J. et al. Platelet-Rich Plasmain a Murine Model: Leukocytes, Growth Factors, Flt-1, and Muscle Healing // Am.J. Sports Med. ‒ 2016. ‒ Vol. 44, № 8. ‒ P. 1962-1971.111. Dey-Rao R., Sinha A.A. Interactome analysis of gene expressionprofile reveals potential novel key transcriptional regulators of skin pathology invitiligo // Genes Immun.
- 2016. - Vol.17. - P.30-45.112. Dhillon R.S., Schwarz E.M., Maloney M.D. Platelet-rich plasmatherapy - future or trend? // Arthritis Res. Ther. ‒ 2012. ‒ Vol. 14, № 4. ‒ P. 219.113. Dimauro I., Grasso L., Fittipaldi S. et al. Platelet-rich plasma andskeletal muscle healing: a molecular analysis of the early phases of theregeneration process in an experimental animal model // PLoS One. ‒ 2014. ‒ Vol.9, № 7.
‒ P. e102993.114. Dinarello C.A., van der Meer J.W. Treating inflammation by blockinginterleukin-1 in humans // Semin. Immunol. - 2013. - Vol.25(6). - P.469-484.115. Dong L., Li Y., Cao J. et al. FGF2 regulates melanocytes viabilitythrough the STAT3-transactivated PAX3 transcription // Cell Death Differ. - 2012.- Vol.19(4). - P.616-622.116. Donovan J. Successful treatment of corticosteroid-resistant ophiasistype alopecia areata (AA) with platelet-rich plasma (PRP) // JAAD Case Rep. ‒2015. ‒ Vol. 1, № 5.
‒ P. 305-307.117. Dwivedi M., Laddha N.C., Arora P. et al. Decreased regulatory T-cellsand CD4(+) /CD8(+) ratio correlate with disease onset and progression in patientswith generalized vitiligo // Pigment Cell Melanoma Res. ‒ 2013. ‒ Vol. 26, № 4. ‒P. 586-591.118. Dwivedi M., Laddha N.C., Shajil E.M. et al. The ACE gene I/ Dpolymorphism is not associated with generalized vitiligo susceptibility in Gujarat112population // Pigment Cell Melanoma Res.
‒ 2008. ‒ Vol. 21, № 3. ‒ P. 407-408.119. Ebanks J.P., Koshoffer A., Wickett R.R. et al. Hydrolytic enzymes ofthe interfollicular epidermis differ in expression and correlate with the phenotypicdifference observed between light and dark skin // J. Dermatol.-2013. -Vol.40(1).- P.27-33120. Edwards C. Measurement of vitiligo: human vs.
Machine // Br. J.Dermatol. - 2019. - Vol.180(5). - P.991.121. Eleftheriadou V., Whitton M.E., Gawkrodger D.J. et al. Futureresearch into the treatment of vitiligo: where should our priorities lie? Results ofthe vitiligo priority setting partnership // Br. J. Dermatol. - 2011. - Vol.164. P.530-536.122. Elela M.A., Hegazy R.A., Fawzy M.M. et al. Interleukin 17,interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo:a case- controlled study on eighty-four patients // Eur. J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
